The LPS receptor (CD14) links innate immunity with Alzheimer's disease

To rapidly respond to invading microorganisms, humans call on their innate immune system. This occurs by microbe‐detecting receptors, such as CD14, that activate immune cells to eliminate the pathogens. Here, we link the lipopolysaccharide receptor CD14 with Alzheimer's disease, a severe neurodegenerative disease resulting in dementia. We demonstrate that this key innate immunity receptor interacts with fibrils of Alzheimer amyloid peptide. Neutralization with antibodies against CD14 and genetic deficiency for this receptor significantly reduced amyloid peptide induced microglial activation and microglial toxicity. The observation of strongly enhanced microglial expression of the LPS receptor in brains of animal models of Alzheimer's disease indicates a clinical relevance of these findings. These data suggest that CD14 may significantly contribute to the overall neuroinflammatory response to amyloid peptide, highlighting the possibility that the enormous progress currently being made in the field of innate immunity could be extended to research on Alzheimer's disease.

[1]  K. Moore,et al.  CD36 Mediates the Innate Host Response to β-Amyloid , 2003, The Journal of experimental medicine.

[2]  K. Triantafilou,et al.  Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. , 2002, Trends in immunology.

[3]  J. Schwab,et al.  CD14 expression by activated parenchymal microglia/macrophages and infiltrating monocytes following human traumatic brain injury , 2002, Acta Neuropathologica.

[4]  T. Kaisho,et al.  Immunology: Bug detectors , 2001, Nature.

[5]  I. Nagaoka,et al.  Cathelicidin Family of Antibacterial Peptides CAP18 and CAP11 Inhibit the Expression of TNF-α by Blocking the Binding of LPS to CD14+ Cells1 , 2001, The Journal of Immunology.

[6]  R. Ulevitch,et al.  Lipopolysaccharide Is in Close Proximity to Each of the Proteins in Its Membrane Receptor Complex , 2001, The Journal of Biological Chemistry.

[7]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Aasen,et al.  Involvement of CD14 and Toll-Like Receptors in Activation of Human Monocytes by Aspergillus fumigatus Hyphae , 2001, Infection and Immunity.

[9]  S. Rivest,et al.  Toll‐like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram‐negative bacterial cell wall components , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  S. Akira,et al.  CD11b/CD18 Acts in Concert with CD14 and Toll-Like Receptor (TLR) 4 to Elicit Full Lipopolysaccharide and Taxol-Inducible Gene Expression1 2 3 , 2001, The Journal of Immunology.

[11]  H. Petty,et al.  Cutting Edge: Lipopolysaccharide Induces Physical Proximity Between CD14 and Toll-Like Receptor 4 (TLR4) Prior to Nuclear Translocation of NF-κB1 , 2000, The Journal of Immunology.

[12]  T. Bayer,et al.  Subacute NO generation induced by Alzheimer's β‐amyloid in the living brain: reversal by inhibition of the inducible NO synthase , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[14]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[15]  S. L. Yates,et al.  Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP‐1 Cells and Murine Microglia , 2000, Journal of neurochemistry.

[16]  D. Fearon,et al.  Innate immunity: Receptors and effectors of innate immunity: Editorial Overview , 2000 .

[17]  H. Flad,et al.  Binding of lipopolysaccharide (LPS) to CHO cells does not correlate with LPS‐induced NF‐κB activation , 2000, European journal of immunology.

[18]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[19]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[20]  J. Radolf,et al.  Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. , 1998, Journal of immunology.

[21]  D. Munoz,et al.  Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging , 1998, Neurology.

[22]  E. Uemura,et al.  Integrin Mac-1 and β-amyloid in microglial release of nitric oxide , 1997, Brain Research.

[23]  R. Mrak,et al.  Neuritic plaque evolution in Alzheimer’s disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms , 1997, Acta Neuropathologica.

[24]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.

[25]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[26]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[27]  J. Silver,et al.  Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. , 1996, Immunity.

[28]  D. Ferrari,et al.  Activation of microglial cells by β-amyloid protein and interferon-γ , 1995, Nature.

[29]  R. Ulevitch,et al.  Analysis of lipopolysaccharide binding by CD14. , 1993, The Journal of biological chemistry.

[30]  M. Freeman,et al.  Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin. , 1993, The Journal of biological chemistry.

[31]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  V. ter meulen,et al.  Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Krieger,et al.  Recognition and plasma clearance of endotoxin by scavenger receptors , 1991, Nature.

[34]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[35]  B. de Strooper,et al.  A cell biological perspective on Alzheimer's disease. , 2002, Annual review of cell and developmental biology.

[36]  S. Younkin.  Amyloid beta vaccination: reduced plaques and improved cognition. , 2001, Nature medicine.

[37]  H. Petty,et al.  Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. , 2000, Journal of immunology.

[38]  M. Kehrli,et al.  Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide. , 1997, Brain research.

[39]  A. Schmidt,et al.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.

[40]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. , 1996, Nature.

[41]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .